University of Groningen
Novel heart failure biomarkers
Du, Weijie
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date: 2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Du, W. (2019). Novel heart failure biomarkers: Physiological studies to understand their complexity. University of Groningen.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Stellingen
Behorende bij het proefschrift
Novel Heart Failure Biomarkers
Physiological studies to understand their complexity
Weijie Du
1. Understanding tissue and cell origin of biomarkers in relation to different physiological and pathological stress conditions is essential to optimally use biomarkers in clinical care. (This thesis)
2. Levels of cardiac specific biomarkers (e.g. natriuretic peptides) correlate with indices of cardiac function and remodeling. (This thesis and other studies)
3. Plasma levels of non cardiospecific markers (e.g. Galectin-3, GDF15 and TIMP1) do not correlate with parameters of cardiac remodeling and function.
4. The plasma levels of non cardiospecific markers reflect enhanced expression in multiple stressed tissues and organs and this may explain their robust prognostic value in systemic heart failure syndrome. (This thesis)
5. Galectin-3 plasma levels are strongly elevated in obese mice and this correlates with highly elevated adipose tissue expression. (This thesis)
6. Numerous clinical associative biomarker studies have been performed but these have helped little in understanding what biomarkers tell us. Animal studies will be required to go beneath the surface and provide a more detailed picture. (This thesis)
7. Induction of miR-328 expression after myocardial infarction is pro-fibrotic, and its inhibition with an antagomir diminishes interstitial fibrosis, indicating that this has therapeutic potential. (This thesis)
8. Pharmacological inhibition of myeloperoxidase (MPO) is able to delay, but cannot halt, progressive cardiac remodeling upon pressure overload, but in cardiac inflammatory diseases it may have more potential. (This thesis).
9. Pharmacological targeting of plasma biomarkers may have value in heart disease, but understanding the exact role of these biomarkers in cardiac disease will be required for designing tailored-therapy.
10. Clinical studies of biomarkers are easy to perform and publish, but this has paradoxically delayed the advance of the biomarker field in heart failure and beyond.
11. Although the road is endless and far away, I still want to pursue the truth in the world. 路漫漫 其修远兮，吾将上下而求索。《离骚》
